Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 30;58(S1):90-95.
doi: 10.5045/br.2023.2023052.

Plasmacytoid dendritic cell neoplasms

Yoo Jin Lee  1 , Youjin Kim  1 , Sang Hyuk Park  2 , Jae-Cheol Jo  1
Affiliations
Review

Plasmacytoid dendritic cell neoplasms

Yoo Jin Lee et al. Blood Res. .

Abstract

Plasmacytoid dendritic cells (pDCs) are type I interferon-producing cells that modulate immune responses. There are two types of pDC neoplasms: 1) mature pDC proliferation (MPDCP) associated with myeloid neoplasm and 2) blastic pDC neoplasm (BPDCN). MPDCP is a clonal expansion of mature pDCs that is predominantly associated with chronic myelomonocytic leukemia. In contrast, BPDCN is a clinically aggressive myeloid malignancy involving the skin, bone marrow, lymphatic organs, and central nervous system. There are various types of skin lesions, ranging from solitary brown or violaceous to disseminated cutaneous lesions, which often spread throughout the body. The expression of CD4, CD56, CD123, and pDC markers (TCL-1, TCF4, CD303, and CD304, etc.) are typical immunophenotype of BPDCN. Historically, BPDCN treatment has been based on acute leukemia regimens and allogeneic hematopoietic cell transplantation in selected patients. Recent advances in molecular biology and genetics have led to the development of targeted agents, such as tagraxofusp (a recombinant fusion protein targeting CD123), anti-CD123 CAR-T cells, XmAb14045, and IMGN632. Lastly, this review provides a comprehensive overview of pDC neoplasms.

Keywords: Blastic plasmacytoid dendritic cell neoplasm; Mature plasmacytoid dendritic cell proliferation; Plasmacytoid dendritic cell neoplasm.

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Differential diagnosis of hematologic malignancies with plasmacytoid dendritic cells.
See this image and copyright information in PMC

References

    1. Lennert K, Remmele W. Karyometrische untersuchungen an lymphknotenzellen des menschen. Acta Haematol. 1958;19:99–113. doi: 10.1159/000205419. - DOI - PubMed
    1. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97:3210–7. doi: 10.1182/blood.V97.10.3210. - DOI - PubMed
    1. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells physiologic roles and pathologic states. Adv Anat Pathol. 2009;16:392–404. doi: 10.1097/PAP.0b013e3181bb6bc2. - DOI - PMC - PubMed
    1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed
    1. El Hussein S, Wang W. Plasmacytoid dendritic cells in the setting of myeloid neoplasms: diagnostic guide to challenging pathologic presentations. Br J Haematol. 2023;200:545–55. doi: 10.1111/bjh.18632. - DOI - PubMed